Mr Narasimha Chava

Biography

Narasimha Chava is a Quality Assurance (QA) Manager at the Global Health Trials Unit (GHTU) and Human Challenge Facility (HCF) at Liverpool School of Tropical Medicine (LSTM), where he oversees the Quality Management System (QMS) across both units. His role focuses on ensuring compliance with Good Clinical Practice (GCP) and regulatory requirements, safeguarding participant safety, rights, and the integrity of clinical trial data. He leads key quality activities including audit planning and execution, inspection readiness, SOP development, training delivery, and implementing risk-based quality oversight and compliance monitoring activities.

Narasimha has experience in both clinical trials and post-marketing studies across the UK and internationally, across both commercial and non-commercial sectors, including global studies aligned with UK MHRA, EU EMA, and US FDA requirements, covering therapeutic areas such as women’s health, oncology, nephrology, and immunosuppressants. With an academic background in pharmacy and health services management, he brings strong expertise in global regulatory frameworks, audit requirements, and quality oversight.

He has previously held roles including Drug Safety Associate, Operational Specialist, Governance Officer, and Quality and Risk Lead within leading clinical research organisations. In his current role, Narasimha supports the development and continuous improvement of QMS systems, conducts internal audits, and works closely with research teams to maintain high standards. He also embraces technology to develop tools that support and monitor research activities, reflecting his ongoing commitment to supporting both patients and researchers.

Research interests

Narasimha’s research interests focus on quality assurance and governance in clinical research, particularly the development and implementation of robust Quality Management Systems (QMS) to support compliant and efficient trial conduct using innovative technologies to enhance real-time monitoring, risk management, and overall research quality.

Additionally, his research interests include supporting rapidly evolving regulatory frameworks to enable more streamlined approval processes and effective quality management. He is particularly motivated to contribute to approaches that reduce disease burden and accelerate the delivery of safe and effective therapeutic options to patients.